<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:30:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4669589" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4669589</identifier>
        <datestamp>2015-12-15</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>American Society of Clinical Oncology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4669589</article-id>
              <article-id pub-id-type="pmcid">PMC4669589</article-id>
              <article-id pub-id-type="pmc-uid">4669589</article-id>
              <article-id pub-id-type="pmid">26460303</article-id>
              <article-id pub-id-type="pmid">26460303</article-id>
              <article-id pub-id-type="publisher-id">32497</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.2015.63.2497</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>Gic5</subject>
                  <subject>Gic7</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Gastrointestinal Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase II Pilot Study of Vemurafenib in Patients With Metastatic <italic>BRAF</italic>-Mutated Colorectal Cancer</article-title>
                <alt-title alt-title-type="short">Vemurafenib in <italic>BRAF</italic>-Mutated Colorectal Cancer</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kopetz</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Desai</surname>
                    <given-names>Jayesh</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>Emily</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hecht</surname>
                    <given-names>Joel Randolph</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O'Dwyer</surname>
                    <given-names>Peter J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maru</surname>
                    <given-names>Dipen</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Morris</surname>
                    <given-names>Van</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Janku</surname>
                    <given-names>Filip</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dasari</surname>
                    <given-names>Arvind</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chung</surname>
                    <given-names>Woonbook</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Issa</surname>
                    <given-names>Jean-Pierre J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gibbs</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>James</surname>
                    <given-names>Brian</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Powis</surname>
                    <given-names>Garth</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nolop</surname>
                    <given-names>Keith B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bhattacharya</surname>
                    <given-names>Suman</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saltz</surname>
                    <given-names>Leonard</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1"/>
                </contrib>
                <aff id="aff1">Scott Kopetz, Dipen Maru, Van Morris, Filip Janku, and Arvind Dasari, The University of Texas MD Anderson Cancer Center, Houston, TX; Emily Chan, Vanderbilt-Ingram Cancer Center, Nashville, TN; Joel Randolph Hecht, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; Brian James and Garth Powis, Sanford Burnham Institute, La Jolla; Keith B. Nolop, Plexxikon, Berkeley; Suman Bhattacharya, Genentech, South San Francisco, CA; Peter J. O'Dwyer, Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; Woonbook Chung and Jean-Pierre J. Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA; Leonard Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY; and Jayesh Desai and Peter Gibbs, Royal Melbourne Hospital, Parkville, Victoria, Australia.</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Corresponding author: Scott Kopetz, MD, PhD, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030; e-mail: <email>skopetz@mdanderson.org</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>1</day>
                <month>12</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>9</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>21</day>
                <month>9</month>
                <year>2015</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
              <volume>33</volume>
              <issue>34</issue>
              <fpage>4032</fpage>
              <lpage>4038</lpage>
              <permissions>
                <copyright-statement>© 2015 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2015</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/us/">
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 3.0 License: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/us/">http://creativecommons.org/licenses/by-nc-nd/3.0/us/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zlj03415004032.pdf"/>
              <abstract>
                <sec>
                  <title>Purpose</title>
                  <p><italic>BRAF</italic> V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral <italic>BRAF</italic> V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with <italic>BRAF</italic> V600E–positive metastatic CRC was unknown.</p>
                </sec>
                <sec>
                  <title>Patients and Methods</title>
                  <p>In this multi-institutional, open-label study, patients with metastatic CRC with <italic>BRAF</italic> V600 mutations were recruited to an expansion cohort at the previously determined maximum-tolerated dose of 960 mg orally twice a day.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Twenty-one patients were enrolled, of whom 20 had received at least one prior metastatic chemotherapy regimen. Grade 3 toxicities included keratoacanthomas, rash, fatigue, and arthralgia. Of the 21 patients treated, one patient had a confirmed partial response (5%; 95% CI, 1% to 24%) and seven other patients had stable disease by RECIST criteria. Median progression-free survival was 2.1 months. Patterns of concurrent mutations, microsatellite instability status, CpG island methylation status, PTEN loss, EGFR expression, and copy number alterations were not associated with clinical benefit. In contrast to prior expectations, concurrent <italic>KRAS</italic> and <italic>NRAS</italic> mutations were detected at low allele frequency in a subset of the patients' tumors (median, 0.21% allele frequency) and were apparent mechanisms of acquired resistance in vemurafenib-sensitive patient-derived xenograft models.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>In marked contrast to the results seen in patients with <italic>BRAF</italic> V600E–mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with <italic>BRAF</italic> V600E mutant CRC. Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of <italic>KRAS</italic> and <italic>NRAS</italic> mutations.</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>INTRODUCTION</title>
              <p><italic>BRAF</italic> mutations are present in between 5% and 15% of colorectal cancer (CRC). Classically, these mutations are common in the sessile serrated adenoma pathway of adenoma to carcinoma progression and are associated with unique molecular features, including microsatellite instability, hypermethylation, and minimal chromosomal instability.<sup><xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref></sup>
<italic>BRAF</italic> mutations are present at higher frequency in right-sided tumors and are more likely to present with poorly differentiated and node-positive tumors. <italic>BRAF</italic> mutations frequently coexist with high microsatellite instability and provide modest prognostic information for recurrence.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref></sup> Patients with metastatic <italic>BRAF</italic>-mutated CRC have a poor prognosis, with a median survival of approximately 12 months despite the utilization of combination chemotherapy.<sup><xref rid="B6" ref-type="bibr">6</xref></sup></p>
              <p>The mutation of a valine to glutamate in codon 600 in the <italic>BRAF</italic> kinase domain (V600E) results in a constitutively active protein. The V600E mutation accounts for approximately 95% of the activating mutations in <italic>BRAF</italic> in CRC. This mutation results in activation of the MAPK pathway, as highlighted by the near mutual exclusivity with activating mutations in <italic>KRAS</italic> and <italic>NRAS</italic>. The unique conformation induced by V600E mutations is inhibited by vemurafenib, a kinase inhibitor designed to have increased affinity for the mutated form of <italic>BRAF</italic>. Treatment with vemurafenib has demonstrated a high response rate and prolonged progression-free survival in <italic>BRAF</italic> mutant melanoma, leading to US Food and Drug Administration approval for this indication.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Preclinical studies in <italic>BRAF</italic> mutant CRC cell line models suggested activity with vemurafenib, with growth arrest and inhibition of MAPK signaling, and provided a strong rationale for clinical evaluation.<sup><xref rid="B8" ref-type="bibr">8</xref></sup></p>
              <p>However, the activity of vemurafenib in patients with CRC with <italic>BRAF</italic> V600 mutations had not been defined. Therefore, we conducted a multisite expansion cohort on the phase I trial of vemurafenib after establishment of the recommended phase II dose in melanoma.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> To explore the biology and potential predictive markers of response to therapy, we subjected patient material for correlative studies based on the emerging data on the distinct biology of <italic>BRAF</italic> mutant CRC.</p>
            </sec>
            <sec sec-type="subjects|methods">
              <title>PATIENTS AND METHODS</title>
              <sec>
                <title>Eligibility Criteria</title>
                <p>For the CRC expansion cohort, eligible patients had metastatic CRC with centrally confirmed V600E-positive <italic>BRAF</italic>, evaluable or measurable disease by RECIST version 1.0, and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients also had to be ≥ 18 years old with adequate hematopoietic, hepatic, and kidney function and a life expectancy ≥ 3 months. Key exclusion criteria included chemotherapy within 2 weeks, prior therapy with targeted agents against <italic>BRAF</italic> or <italic>MEK</italic>, uncontrolled CNS metastases, and mean QTc ≥ 500 milliseconds. Given the risk of squamous cell carcinoma (SCC) with <italic>BRAF</italic> inhibition, patients were required to be free of pre-existing nonmelanoma skin lesions including keratoacanthoma, actinic keratosis, and squamous carcinoma in situ. The protocol (ClinicalTrials.gov identifier: NCT00405587) was approved by the institutional review boards of all participating institutions, and written informed consent was obtained for all patients before performing study-related procedures.</p>
              </sec>
              <sec>
                <title>Drug Administration and Study Design</title>
                <p>Vemurafenib was provided in microprecipitated bulk powder formulation as 240-mg film-coated tablets, dosed at the previously determined maximum-tolerated dose of 960 mg orally twice a day, and administered continuously in 28-day cycles.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Patients underwent history and physical examination, CBC, chemistries, coagulation parameters, urinalysis, carcinoembryonic antigen, ECG, and tumor measurements within 3 weeks before start of therapy. While on study, patients underwent evaluations, including brief history and physical examination, vital signs, urinalysis, CBC, and chemistries, on days 8, 15, and 29 during cycle 1 and on day 1 of each subsequent cycle. ECGs were performed at baseline and before cycle 2. Adverse events were classified according to the Common Terminology Criteria of Adverse Events (version 3.0). Response was assessed radiographically after every two cycles or more frequently at the treating physician's discretion. Given the risk of SCC with <italic>BRAF</italic> inhibition, dermatologic, head, neck, and chest (with chest computed tomography) monitoring for SCC were performed at baseline and periodically thereafter.</p>
              </sec>
              <sec>
                <title>Pharmacokinetic Studies</title>
                <p>Pharmacokinetic samples were obtained on days 1 and 15 (before dose and 0.5, 1, 2, 4, and 8 hours after dose), day 16 (before dose), and day 29 (before dose). During continued dosing, pharmacokinetic samples were obtained before dose once every 4 weeks. Vemurafenib plasma concentration was evaluated by noncompartmental methods. Pharmacokinetic samples were also collected from the parallel expansion cohort in melanoma, as previously reported.<sup><xref rid="B9" ref-type="bibr">9</xref></sup></p>
              </sec>
              <sec>
                <title>Correlative Studies</title>
                <p>DNA was extracted from macrodissected tumor on formalin-fixed paraffin-embedded (FFPE) slides, including hematoxylin and eosin–stained reference slide according to manufacturer methods (Qiagen DNeasy, Qiagen, Hilden, Germany; and Epicentre, Madison, WI).<sup><xref rid="B10" ref-type="bibr">10</xref></sup> To determine copy number and hotspot gene mutations, the tumor was subjected to OncoScan FFPE Express V2 (Affymetrix, Santa Clara, CA) and Sequenom MassARRAY (Sequenom, San Diego, CA), both of which were optimized for use of FFPE samples with a sensitivity of 10% mutant alleles. The mutations detected are included in hotspot regions in <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>PIK3CA</italic>, and <italic>AKT</italic>, among others (Data Supplement). Copy number alterations were determined by segmentation analysis produced by Nexus Copy Number (BioDiscovery, El Segundo, CA). PTEN and EGFR protein expression was determined using immunohistochemistry as previously described (PTEN clone 6H2.1, Dako, Carpinteria, CA; EGFR clone 31G7, Zymed, San Francisco, CA).<sup><xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref></sup> Methylation analysis was performed to classify patients based on the degree of tumor methylation using bisulfite polymerase chain reaction (PCR) followed by pyrosequencing for a previously established six-marker CpG island methylator phenotype (CIMP) panel (MINT1, MINT2, MINT31, hMLH1, p16, and p14).<sup><xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref></sup></p>
                <p>To assess low-frequency clones, DNA was subjected to emulsion PCR (BEAMing, Sysmex Inostics, Baltimore, MD), a methodology to perform single-molecule PCRs on magnetic beads in water-in-oil emulsions, followed by allele-specific hybridization and flow cytometry–based allele quantification with sensitivity of 0.15% on FFPE tissue specimens (Data Supplement).<sup><xref rid="B15" ref-type="bibr">15</xref></sup> A complementary droplet digital PCR was applied to a second cohort of 19 <italic>BRAF</italic> mutant tumors from patients not treated on the protocol but obtained from the Royal Melbourne Hospital (Parkville, Victoria, Australia). Analyzes were performed with a droplet digital PCR <italic>KRAS</italic> screening multiplex kit (BioRad QX100, BioRad, Hercules, CA) according to the manufacturer's instructions, with sensitivity to 0.15% mutant allele frequency for FFPE samples and 0.05% for fresh tissue. Patient-derived xenografts were derived from core biopsies and implanted in NOD-SCID-γ mice (Jackson Labs, Bar Harbor, ME). Established tumors were treated with vemurafenib analog PLX4720. Tumor sequencing of the resistant xenograft tumors for 409 exons was performed by Ion AmpliSeq Comprehensive Cancer Panel on the Ion Torrent PGM (Life Technologies, Carlsbad, CA).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec>
                <title>Patient Characteristics and Treatment</title>
                <p>Twenty-one patients with <italic>BRAF</italic> V600E mutation–positive metastatic CRC (20 colon cancers and one rectal cancer) were enrolled at multiple institutions in the United States and Australia. Of the 21 patients, 11 were men and 10 were women, with a median age of 65 years (range, 38 to 91 years; <xref ref-type="table" rid="T1">Table 1</xref>). Baseline Eastern Cooperative Oncology Group performance status was 0 and 1 in 11 and 10 patients, respectively. Results from local standard <italic>KRAS</italic> testing (codons 12 and 13) were available for 16 of the 21 patients, with all tumors characterized as wild type. All patients received prior therapy, and all except one patient received at least one prior chemotherapy regimen in the metastatic setting; 14 patients received at least two lines. Consistent with the known chemotherapy-refractory nature of the disease, only three of the 20 previously treated patients achieved a partial response to prior chemotherapy treatments.<sup><xref rid="B16" ref-type="bibr">16</xref></sup></p>
                <table-wrap id="T1" position="float">
                  <label>Table 1.</label>
                  <caption>
                    <p>Baseline Demographic and Clinical Characteristics</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="zlj03415-5656-t01"/>
                    <table frame="box" rules="groups">
                      <thead valign="bottom">
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Characteristic</th>
                          <th align="center" rowspan="1" colspan="1">No. of Patients</th>
                          <th align="center" rowspan="1" colspan="1">%</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Sex</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Male</td>
                          <td align="char" char="." rowspan="1" colspan="1">11</td>
                          <td align="char" char="." rowspan="1" colspan="1">52</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Female</td>
                          <td align="char" char="." rowspan="1" colspan="1">10</td>
                          <td align="char" char="." rowspan="1" colspan="1">48</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age, years</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Median</td>
                          <td align="center" colspan="2" rowspan="1">65</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Range</td>
                          <td align="center" colspan="2" rowspan="1">38-91</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">ECOG performance status</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    0</td>
                          <td align="char" char="." rowspan="1" colspan="1">11</td>
                          <td align="char" char="." rowspan="1" colspan="1">52</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    1</td>
                          <td align="char" char="." rowspan="1" colspan="1">10</td>
                          <td align="char" char="." rowspan="1" colspan="1">48</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Race</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    White</td>
                          <td align="char" char="." rowspan="1" colspan="1">19</td>
                          <td align="char" char="." rowspan="1" colspan="1">91</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Asian</td>
                          <td align="char" char="." rowspan="1" colspan="1">2</td>
                          <td align="char" char="." rowspan="1" colspan="1">9</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Previous therapies</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Surgery</td>
                          <td align="char" char="." rowspan="1" colspan="1">21</td>
                          <td align="char" char="." rowspan="1" colspan="1">100</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Chemotherapy</td>
                          <td align="char" char="." rowspan="1" colspan="1">20</td>
                          <td align="char" char="." rowspan="1" colspan="1">95</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Radiation</td>
                          <td align="char" char="." rowspan="1" colspan="1">2</td>
                          <td align="char" char="." rowspan="1" colspan="1">10</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">No. of previous therapies for metastatic disease</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    0</td>
                          <td align="char" char="." rowspan="1" colspan="1">1</td>
                          <td align="char" char="." rowspan="1" colspan="1">5</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    1</td>
                          <td align="char" char="." rowspan="1" colspan="1">1</td>
                          <td align="char" char="." rowspan="1" colspan="1">5</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    2</td>
                          <td align="char" char="." rowspan="1" colspan="1">4</td>
                          <td align="char" char="." rowspan="1" colspan="1">19</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    ≥ 3</td>
                          <td align="char" char="." rowspan="1" colspan="1">15</td>
                          <td align="char" char="." rowspan="1" colspan="1">71</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="abbr">
                      <p>Abbreviation: ECOG, Eastern Cooperative Oncology Group.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Safety</title>
                <p>The most common toxicities of any grade while on treatment were fatigue, hyperglycemia, proteinuria, and diarrhea (<xref ref-type="table" rid="T2">Table 2</xref>). There were no grade 4 toxicities, and the most common grade 3 toxicity was SCC of the skin (a Common Terminology Criteria for Adverse Events term that was inclusive of keratoacanthomas). Overall, 15 of 21 patients experienced at least one grade 3 AE while on study, with seven patients experiencing severe adverse events attributed to the therapy. There were no toxicity-related discontinuations or deaths, but 52% of patients (11 patients) had AEs leading to dose interruption across all cycles. The most common causes of dose interruption included rash (n = 4), elevated liver function tests (n = 2), and diarrhea (n = 2). Furthermore, 19% of patients (four patients) required one or more dose reductions secondary to drug-related toxicities of rash, fatigue, nausea, or anorexia.</p>
                <table-wrap id="T2" position="float">
                  <label>Table 2.</label>
                  <caption>
                    <p>Summary of All Adverse Events While Receiving Treatment in ≥ 25% of Patients, Irrespective of Causality</p>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="zlj03415-5656-t02"/>
                    <table frame="box" rules="groups">
                      <thead valign="bottom">
                        <tr>
                          <th align="center" rowspan="2" colspan="1">Adverse Event</th>
                          <th align="center" colspan="2" rowspan="1">No. of Patients (%)<hr/></th>
                        </tr>
                        <tr>
                          <th align="center" rowspan="1" colspan="1">Grade ≥ 3</th>
                          <th align="center" rowspan="1" colspan="1">All Grades</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Squamous cell carcinoma of skin<xref ref-type="table-fn" rid="TF2-1">*</xref></td>
                          <td align="char" char="(" rowspan="1" colspan="1">5 (23.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">5 (23.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hyperbilirubinemia</td>
                          <td align="char" char="(" rowspan="1" colspan="1">3 (14.3)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Rash</td>
                          <td align="char" char="(" rowspan="1" colspan="1">2 (9.5)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hyponatremia</td>
                          <td align="char" char="(" rowspan="1" colspan="1">2 (9.5)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">6 (28.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Fatigue</td>
                          <td align="char" char="(" rowspan="1" colspan="1">1 (4.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">13 (61.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diarrhea</td>
                          <td align="char" char="(" rowspan="1" colspan="1">1 (4.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">8 (38.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Arthralgia</td>
                          <td align="char" char="(" rowspan="1" colspan="1">1 (4.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">8 (38.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Vomiting</td>
                          <td align="char" char="(" rowspan="1" colspan="1">1 (4.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Lymphopenia</td>
                          <td align="char" char="(" rowspan="1" colspan="1">1 (4.8)</td>
                          <td align="char" char="(" rowspan="1" colspan="1">6 (28.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Proteinuria</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">9 (42.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Photosensitivity reaction</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hyperglycemia</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Nausea</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">7 (33.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hypoalbuminemia</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">6 (28.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Pyrexia</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">6 (28.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Headache</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="char" char="(" rowspan="1" colspan="1">6 (28.6)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn fn-type="other" id="TF2-1">
                      <label>*</label>
                      <p>Cutaneous squamous cell carcinomas were reported as grade 3 adverse events, and a majority were managed by excision. One patient required treatment discontinuation for numerous lesions unable to be adequately managed by excision.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Patients were monitored closely and underwent scheduled skin exams by dermatologists during therapy. Five patients developed new cutaneous SCCs while on treatment (Appendix <xref ref-type="fig" rid="FA1">Fig A1</xref>, online only). In addition, two patients developed seborrheic dermatitis, and one patient each developed a skin papilloma and actinic keratosis. There were no SCCs at other monitored sites including the head, neck, and lung. Other cutaneous adverse events included photosensitivity in 33.3% (seven patients), rash in 19% (four patients), dry skin in 24% (five patients), pruritus in 14% (three patients), and hyperkeratosis in 10% (two patients).</p>
                <p>Given the reported potential for vemurafenib to induce QT prolongation, ECGs were evaluated at baseline and the beginning of cycle 2, with a mean increase in QTc of 12.5 milliseconds (standard deviation, 17.8 milliseconds). Three patients experienced an increase greater than 30 milliseconds and less than 45 milliseconds.</p>
                <p>Pharmacokinetic studies were available on all patients. When compared with melanoma patients in the concurrently enrolled cohort, there was no statistically significant difference in vemurafenib concentration after the first dose (mean ± standard deviation: maximum concentration, 5.5 ± 2.3 μg/mL; area under the curve from 0 to 8 hours, 31.5 ± 15.1 μg/mL·h; Appendix <xref ref-type="fig" rid="FA2">Fig A2</xref>, online only). Thirteen patients were available for day 15 sampling, with a maximum concentration of 38.6 ± 15.9 μg/mL and area under the curve from 0 to 8 hours of 262.4 ± 101.4 μg/mL·h.</p>
              </sec>
              <sec>
                <title>Antitumor Activity</title>
                <p>Nineteen of the 21 patients in this trial had postbaseline scans. There were no complete responses. One patient had a confirmed partial response, which was durable for 21 weeks. Seven other patients had stable disease as best response for at least 8 weeks (range, 8 to 50 weeks; <xref ref-type="fig" rid="F2">Fig 2</xref>A). Ten patients had some degree of tumor shrinkage on the first planned computed tomography scan. Three patients had pretreatment and follow-up [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography; two of these patients had a metabolic response with greater than 25% reduction in standard uptake value (Appendix <xref ref-type="fig" rid="FA3">Fig A3</xref>, online only). The median progression-free survival was 2.1 months (range, 0.4 to 11.6 months), with two patients free from progression for more than 6 months. Median overall survival time was 7.7 months (range, 1.4 to 13.1 months).</p>
                <fig id="F1" position="float">
                  <label>Fig 1.</label>
                  <caption>
                    <p>(A) Waterfall plot of best RECIST response to vemurafenib in evaluable patients. (*) Fifty-nine percent growth from baseline. (†) Patients with notable mixed responses. (B) Progression-free survival. (C) Overall survival.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560001"/>
                </fig>
                <fig id="F2" position="float">
                  <label>Fig 2.</label>
                  <caption>
                    <p>Correlation of best overall response rate with molecular characterization. Gray boxes represent samples unable to be analyzed for the specified assay. Numbers in the copy number (CN) alteration boxes represent the number of unique segments with CN alterations. Percentages in the RAS clone box represent mutant allele frequency. (*) Not evaluable for response.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560002"/>
                </fig>
              </sec>
              <sec>
                <title>Correlative Biomarkers</title>
                <p>To evaluate the lower than expected overall response rate (compared with that seen in melanoma) and heterogeneous response to therapy in some patients, baseline tumor tissue from requested archival FFPE slides was analyzed for molecular and protein biomarkers in exploratory analyses. Prior preclinical studies had suggested that activation of the PI3K pathway may be associated with resistance to <italic>BRAF</italic> inhibition based on correlation to sensitivity in a panel of <italic>BRAF</italic> mutant CRC cell lines.<sup><xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B17" ref-type="bibr">17</xref></sup> The PI3K pathway was activated by complete loss of PTEN protein staining or mutations in <italic>PIK3CA</italic> or <italic>AKT</italic> in four of 14 evaluable tumors, with no association with response to therapy (Appendix <xref ref-type="fig" rid="FA4">Fig A4</xref>, online only). Because EGFR has been implicated in feedback activation of the MAPK pathway after <italic>BRAF</italic> inhibition, total expression of EGFR in the tumor was evaluated as a potential predictive biomarker. When dichotomized based on any expression versus no expression, there was no correlation with tumor response (Appendix <xref ref-type="fig" rid="FA4">Fig A4</xref>B).</p>
                <p>Hypermethylation is a nearly universal feature of tumors with <italic>BRAF</italic> mutations, and analysis of a previously established six-gene CIMP panel confirmed this finding.<sup><xref rid="B18" ref-type="bibr">18</xref></sup> The pattern of methylation in these markers has been previously used to subclassify CIMP-high tumors but did not correlate with clinical activity in this cohort. Complete loss of hMLH1 by protein expression was seen in patients with methylation of hMLH1 in the promoter region and defined a subset of patients (four of 15 patients) with a high level of microsatellite instability. Tumors were further annotated by the number of unique segments with copy number alterations. The expected inverse correlation between higher levels of copy number alteration and microsatellite instability was seen, but neither correlated with radiographic response.</p>
                <p>Prior studies have demonstrated the presence of rare <italic>KRAS</italic> or <italic>NRAS</italic> clones that can lead to resistance in patients treated with EGFR monoclonal antibodies. To explore whether a similar finding is seen in <italic>BRAF</italic>-mutated CRC, tumors were subjected to a high-sensitivity emulsion PCR methodology to evaluate for the presence of rare <italic>KRAS</italic> or <italic>NRAS</italic> mutant clones in the pretreatment tissue. Low-frequency <italic>KRAS</italic> or <italic>NRAS</italic> mutations were seen in nine of 16 evaluable tumors (56%), with a median allele frequency of 0.21% (interquartile range, 0.18% to 0.42%; <xref ref-type="fig" rid="F3">Fig 3</xref>A). These mutations were not detected by standard-of-care clinical sequencing or mass spectroscopy genotyping with a sensitivity of 10%. There was no correlation of the presence of low-frequency alleles with radiographic response or duration of treatment. To confirm this finding, a second cohort of primary <italic>BRAF</italic> V600E mutant CRC tumors was evaluated for low-frequency <italic>KRAS</italic> mutations by an independent digital PCR methodology. Thirteen (68%) of the 19 tumors evaluated demonstrated detectable <italic>KRAS</italic> mutations at a median allele frequency of 0.31% (interquartile range, 0.24% to 0.61%). Postprogression tissue was not available from patients who initially developed a response to directly determine the clinical relevance of these low-frequency mutations. Instead, we treated a vemurafenib-sensitive <italic>BRAF</italic> V600E patient-derived xenograft with vemurafenib until progression and explored mechanisms of resistance (<xref ref-type="fig" rid="F3">Fig 3</xref>B). In both cases, the implanted tumor had low-frequency <italic>KRAS</italic> clones present at 0.07% and 0.08% by droplet digital PCR. Tumor regression was seen before development of resistance within 8 weeks. Two separate resistant tumors were sequenced, confirming persistent presence of <italic>BRAF</italic> V600E, with <italic>KRAS</italic> G12D or G12R mutations present at an allele frequency of greater than 40%.</p>
                <fig id="F3" position="float">
                  <label>Fig 3.</label>
                  <caption>
                    <p>(A) Rare <italic>KRAS</italic>-mutant (mut) clones were detected in a validated cohort of <italic>BRAF</italic> V600E–mutant colorectal cancer tumors by droplet digital polymerase chain reaction (ddPCR). (*) Lower limit of detection for clinical sequencing is approximately 5% to 20% depending on assays used. (†) Lower limit of detection for ddPCR. (B) A patient-derived xenograft model developed resistance to vemurafenib analog PLX4720 provided through ad lib chow at a dose of 417 mg/kg. Gray represents control arm; blue and gold represent PLX4720 treatment arm with acquisition of <italic>KRAS</italic> G12R and G12D mutations, respectively.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560003"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>CRCs with mutations in <italic>BRAF</italic> V600E represent a unique CRC subtype with poor prognosis and limited response to standard-of-care therapies. In contrast to melanoma, the tumors have limited response to single-agent <italic>BRAF</italic> inhibition. This discrepancy is not attributed to differences in dose-limiting adverse events or pharmacokinetics but is tumor specific and suggests either differences in oncogene dependency or pharmacodynamic failure as a result of feedback mechanisms. The presence of the mutation in early sessile serrated adenomas and the ability of the <italic>BRAF</italic> V600E mutation to recapitulate tumor development in a genetically engineered mouse model of CRC suggest that this mutation is a driver mutation important for carcinoma initiation.<sup><xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref></sup> The population of enrolled patients with <italic>BRAF</italic> mutant CRC reflected the anticipated molecular phenotype, with high levels of DNA methylation, few copy number alterations, and enrichment for microsatellite instability. Our results demonstrate no meaningful differences in pharmacokinetics between patients with CRC and melanoma, with similar adverse event profiles and administered dose-intensity.<sup><xref rid="B21" ref-type="bibr">21</xref></sup> Although vemurafenib is a substrate for cellular drug exporters such as P-glycoprotein, which is upregulated in CRC relative to melanoma, a similar low response rate (one responder) with the non–P-glycoprotein substrate <italic>BRAF</italic> inhibitor dabrafenib has been reported in patients with CRC.<sup><xref rid="B22" ref-type="bibr">22</xref></sup></p>
              <p>Preclinical work has suggested that the MAPK pathway is insufficiently inhibited with single-agent <italic>BRAF</italic> inhibition in CRC, in contrast to what is considered adequate inhibition in melanoma, irrespective of the <italic>BRAF</italic> inhibitor used.<sup><xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref></sup> This alone may be sufficient to limit clinical activity in CRC. In addition, in the clinical setting in melanoma, there seems to be a threshold of inhibition as measured by phospho-Erk expression required to induce response.<sup><xref rid="B25" ref-type="bibr">25</xref></sup> Because this study did not incorporate on-study biopsies, direct assessment of the ability of vemurafenib to sufficiently inhibit the MAPK pathway is not possible. Preclinical studies since this clinical trial was first reported have added considerably to our understanding of MAPK inhibition and early reactivation of the pathway in CRC, with perhaps the most compelling reactivation being through feedback EGFR reactivation.<sup><xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref></sup> It has been proposed that EGFR expression levels may predict for this reactivation; however, no correlation was seen between total EGFR expression in the primary tumor and clinical activity in our study, suggesting that baseline EGFR expression may be a poor correlate of subsequent EGFR pathway reactivation after <italic>BRAF</italic> inhibition. The combination of EGFR and vemurafenib is being explored in several clinical trials, with some promising early results with panitumumab and an ongoing randomized study of cetuximab and irinotecan, with or without vemurafenib (ClinicalTrials.gov identifier: NCT02164916).<sup><xref rid="B26" ref-type="bibr">26</xref></sup> In contrast, prior preclinical studies suggested that PI3K pathway activation may be associated with resistance to <italic>BRAF</italic> inhibition. However, neither PTEN protein loss nor <italic>PIK3CA</italic> mutation was correlated with resistance in our study, consistent with the limited additional clinical activity seen with the addition of a PI3K inhibitor to BRAF and EGFR inhibition.<sup><xref rid="B27" ref-type="bibr">27</xref></sup></p>
              <p>The finding of <italic>KRAS</italic> and <italic>NRAS</italic> mutations with low allele frequency in the <italic>BRAF</italic> mutant tumors is unexpected. With rare exception, <italic>BRAF</italic> V600E and <italic>KRAS</italic>/<italic>NRAS</italic> mutations are mutually exclusive when assessed by standard sensitivity sequencing.<sup><xref rid="B28" ref-type="bibr">28</xref>–<xref rid="B30" ref-type="bibr">30</xref></sup> Acquisition of <italic>NRAS</italic> mutations has been described as a mechanism of resistance to <italic>BRAF</italic> inhibition in melanoma, and our patient-derived xenograft models suggest that a similar mechanism may be present in <italic>BRAF</italic>-sensitive CRCs.<sup><xref rid="B31" ref-type="bibr">31</xref></sup> Because low allele frequency <italic>KRAS</italic>/<italic>NRAS</italic> mutations have been associated with resistance to cetuximab and current clinical trials are combining <italic>BRAF</italic> and <italic>EGFR</italic> inhibition, there is potential for these low allele frequency <italic>KRAS</italic>/<italic>NRAS</italic> mutations to be important drivers for resistance to the combination. The allele frequency observed in the patient-derived xenograft models is consistent with <italic>BRAF</italic> and <italic>KRAS</italic> mutations coexisting in the same tumor clones, suggesting that strategies to address both mutations will be needed. Evaluation of <italic>KRAS</italic>/<italic>NRAS</italic> mutations should be incorporated into future clinical trials of <italic>BRAF</italic> inhibition, including assessment at the time of progression. Other described mechanisms of acquired resistance in CRC to <italic>BRAF</italic> inhibition in preclinical models and patients include <italic>EGFR</italic>, <italic>KRAS</italic>, and <italic>MET</italic> amplification.<sup><xref rid="B32" ref-type="bibr">32</xref></sup></p>
              <p>The contrast of activity from <italic>BRAF</italic> inhibition in melanoma and CRC has been an important cautionary tale for the trend toward tumor-agnostic, oncogene-defined basket clinical trials. Histology can be a surrogate for potentially important differences in biology. <italic>BRAF</italic>-mutated CRC and melanoma differ in the tissue lineage (endoderm <italic>v</italic> ectoderm, respectively) and concurrent epigenetic features (nearly universal CIMP positive <italic>v</italic> CIMP negative, respectively), among other factors. <italic>BRAF</italic> inhibition has demonstrated some single-agent activity in non–small-cell lung cancer and thyroid cancer, among others, although the magnitude of the benefit remains to be defined.<sup><xref rid="B33" ref-type="bibr">33</xref>,<xref rid="B34" ref-type="bibr">34</xref></sup> In each setting, alternate mechanisms of resistance to <italic>BRAF</italic> inhibition have been proposed, reiterating the concept that tumor histology is still a major determinant of sensitivity to targeted therapies. Further studies should leverage these similarities and differences in <italic>BRAF</italic> inhibition sensitivity to optimize future combination strategies.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="PMC_1" content-type="local-data">
                <caption>
                  <title>Data Supplement</title>
                </caption>
                <media mimetype="text" mime-subtype="html" xlink:href="supp_33_34_4032__index.html"/>
                <media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_33.34.4032_DS_2015.632497.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p>See accompanying editorial on page <related-article id="d36e1110" related-article-type="commentary" ext-link-type="doi" xlink:href="10.1200/JCO.2015.63.7793">3990</related-article> and article on page <related-article id="d36e1113" related-article-type="article-reference" ext-link-type="doi" xlink:href="10.1200/JCO.2015.63.2471">4023</related-article></p>
              </fn>
              <fn fn-type="supported-by">
                <p>Supported by Plexxikon and Roche. The correlative work was supported in part by the National Institutes of Health Cancer Center Support Grant No. CA16670 to The University of Texas MD Anderson Cancer Center. The authors acknowledge support from the National Cancer Institute under Awards No. R01CA172670 (S.K., G.P.), R01 CA160398 (G.P.), and R01CA184843 (S.K.).</p>
              </fn>
              <fn fn-type="conflict">
                <p>Authors' disclosures of potential conflicts of interest are found in the article online at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>. Author contributions are found at the end of this article.</p>
              </fn>
              <fn fn-type="other">
                <p>Clinical trial information: NCT00405587.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgment</title>
              <p>We thank Richard Lee for project management.</p>
            </ack>
            <sec>
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <p>Disclosures provided by the authors are available with this article at <ext-link ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>.</p>
            </sec>
            <sec>
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Scott Kopetz, Jayesh Desai, Peter J. O'Dwyer, Filip Janku, Keith B. Nolop, Suman Bhattacharya, Leonard Saltz</p>
              <p><bold>Financial support:</bold> Scott Kopetz</p>
              <p><bold>Provision of study materials or patients:</bold> Scott Kopetz, Jayesh Desai, Emily Chan, Leonard Saltz</p>
              <p><bold>Collection and assembly of data:</bold> Scott Kopetz, Emily Chan, Joel Randolph Hecht, Peter J. O'Dwyer, Dipen Maru, Van Morris, Arvind Dasari, Woonbook Chung, Peter Gibbs, Brian James, Garth Powis, Keith B. Nolop, Suman Bhattacharya</p>
              <p><bold>Data analysis and interpretation:</bold> Scott Kopetz, Jayesh Desai, Emily Chan, Joel Randolph Hecht, Peter J. O'Dwyer, Dipen Maru, Jean-Pierre J. Issa, Peter Gibbs, Brian James, Garth Powis, Keith B. Nolop, Suman Bhattacharya, Leonard Saltz</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bignell</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Cox</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mutations of the BRAF gene in human cancer</article-title>
                  <source>Nature</source>
                  <year>2002</year>
                  <volume>417</volume>
                  <fpage>949</fpage>
                  <lpage>954</lpage>
                  <pub-id pub-id-type="pmid">12068308</pub-id>
                </element-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Michaloglou</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Vredeveld</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Mooi</surname>
                      <given-names>WJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>BRAF(E600) in benign and malignant human tumours</article-title>
                  <source>Oncogene</source>
                  <year>2008</year>
                  <volume>27</volume>
                  <fpage>877</fpage>
                  <lpage>895</lpage>
                  <pub-id pub-id-type="pmid">17724477</pub-id>
                </element-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Joneson</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bar-Sagi</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Ras effectors and their role in mitogenesis and oncogenesis</article-title>
                  <source>J Mol Med (Berl)</source>
                  <year>1997</year>
                  <volume>75</volume>
                  <fpage>587</fpage>
                  <lpage>593</lpage>
                  <pub-id pub-id-type="pmid">9297626</pub-id>
                </element-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sinicrope</surname>
                      <given-names>FA</given-names>
                    </name>
                    <name>
                      <surname>Shi</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Smyrk</surname>
                      <given-names>TC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes</article-title>
                  <source>Gastroenterology</source>
                  <year>2015</year>
                  <volume>148</volume>
                  <fpage>88</fpage>
                  <lpage>99</lpage>
                  <pub-id pub-id-type="pmid">25305506</pub-id>
                </element-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lochhead</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kuchiba</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Imamura</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2013</year>
                  <volume>105</volume>
                  <fpage>1151</fpage>
                  <lpage>1156</lpage>
                  <pub-id pub-id-type="pmid">23878352</pub-id>
                </element-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tran</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kopetz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tie</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer</article-title>
                  <source>Cancer</source>
                  <year>2011</year>
                  <volume>117</volume>
                  <fpage>4623</fpage>
                  <lpage>4632</lpage>
                  <pub-id pub-id-type="pmid">21456008</pub-id>
                </element-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Flaherty</surname>
                      <given-names>KT</given-names>
                    </name>
                    <name>
                      <surname>Puzanov</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>KB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Inhibition of mutated, activated BRAF in metastatic melanoma</article-title>
                  <source>N Engl J Med</source>
                  <year>2010</year>
                  <volume>363</volume>
                  <fpage>809</fpage>
                  <lpage>819</lpage>
                  <pub-id pub-id-type="pmid">20818844</pub-id>
                </element-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Higgins</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kolinsky</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer</article-title>
                  <source>Cancer Res</source>
                  <year>2012</year>
                  <volume>72</volume>
                  <fpage>779</fpage>
                  <lpage>789</lpage>
                  <pub-id pub-id-type="pmid">22180495</pub-id>
                </element-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abrams</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Mooney</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Zwiebel</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2013</year>
                  <volume>105</volume>
                  <fpage>954</fpage>
                  <lpage>959</lpage>
                  <pub-id pub-id-type="pmid">23776198</pub-id>
                </element-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morikawa</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Shima</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kuchiba</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>No evidence for interference of H&amp;E staining in DNA testing: Usefulness of DNA extraction from H&amp;E-stained archival tissue sections</article-title>
                  <source>Am J Clin Pathol</source>
                  <year>2012</year>
                  <volume>138</volume>
                  <fpage>122</fpage>
                  <lpage>129</lpage>
                  <pub-id pub-id-type="pmid">22706867</pub-id>
                </element-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Varella-Garcia</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Xavier</surname>
                      <given-names>AC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas</article-title>
                  <source>Cancer Prev Res (Phila)</source>
                  <year>2008</year>
                  <volume>1</volume>
                  <fpage>192</fpage>
                  <lpage>200</lpage>
                  <pub-id pub-id-type="pmid">19138956</pub-id>
                </element-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shroff</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Overman</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Rashid</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy</article-title>
                  <source>Arch Pathol Lab Med</source>
                  <year>2013</year>
                  <volume>137</volume>
                  <fpage>1619</fpage>
                  <lpage>1626</lpage>
                  <pub-id pub-id-type="pmid">24168499</pub-id>
                </element-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahn</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Chung</surname>
                      <given-names>WB</given-names>
                    </name>
                    <name>
                      <surname>Maeda</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>DNA methylation predicts recurrence from resected stage III proximal colon cancer</article-title>
                  <source>Cancer</source>
                  <year>2011</year>
                  <volume>117</volume>
                  <fpage>1847</fpage>
                  <lpage>1854</lpage>
                  <pub-id pub-id-type="pmid">21509761</pub-id>
                </element-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colella</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Baggerly</surname>
                      <given-names>KA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites</article-title>
                  <source>Biotechniques</source>
                  <year>2003</year>
                  <volume>35</volume>
                  <fpage>146</fpage>
                  <lpage>150</lpage>
                  <pub-id pub-id-type="pmid">12866414</pub-id>
                </element-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dressman</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Yan</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Traverso</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2003</year>
                  <volume>100</volume>
                  <fpage>8817</fpage>
                  <lpage>8822</lpage>
                  <pub-id pub-id-type="pmid">12857956</pub-id>
                </element-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morris</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Overman</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Jiang</surname>
                      <given-names>ZQ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer</article-title>
                  <source>Clin Colorectal Cancer</source>
                  <year>2014</year>
                  <volume>13</volume>
                  <fpage>164</fpage>
                  <lpage>171</lpage>
                  <pub-id pub-id-type="pmid">25069797</pub-id>
                </element-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mao</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mariadason</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <fpage>657</fpage>
                  <lpage>667</lpage>
                  <pub-id pub-id-type="pmid">23251002</pub-id>
                </element-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shen</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Toyota</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kondo</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2007</year>
                  <volume>104</volume>
                  <fpage>18654</fpage>
                  <lpage>18659</lpage>
                  <pub-id pub-id-type="pmid">18003927</pub-id>
                </element-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beach</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>AO</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>TT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>BRAF mutations in aberrant crypt foci and hyperplastic polyposis</article-title>
                  <source>Am J Pathol</source>
                  <year>2005</year>
                  <volume>166</volume>
                  <fpage>1069</fpage>
                  <lpage>1075</lpage>
                  <pub-id pub-id-type="pmid">15793287</pub-id>
                </element-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coffee</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Faber</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Roper</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <fpage>2688</fpage>
                  <lpage>2698</lpage>
                  <pub-id pub-id-type="pmid">23549875</pub-id>
                </element-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chapman</surname>
                      <given-names>PB</given-names>
                    </name>
                    <name>
                      <surname>Hauschild</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Robert</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title>
                  <source>N Engl J Med</source>
                  <year>2011</year>
                  <volume>364</volume>
                  <fpage>2507</fpage>
                  <lpage>2516</lpage>
                  <pub-id pub-id-type="pmid">21639808</pub-id>
                </element-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Falchook</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Long</surname>
                      <given-names>GV</given-names>
                    </name>
                    <name>
                      <surname>Kurzrock</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial</article-title>
                  <source>Lancet</source>
                  <year>2012</year>
                  <volume>379</volume>
                  <fpage>1893</fpage>
                  <lpage>1901</lpage>
                  <pub-id pub-id-type="pmid">22608338</pub-id>
                </element-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Corcoran</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Ebi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Turke</surname>
                      <given-names>AB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib</article-title>
                  <source>Cancer Discov</source>
                  <year>2012</year>
                  <volume>2</volume>
                  <fpage>227</fpage>
                  <lpage>235</lpage>
                  <pub-id pub-id-type="pmid">22448344</pub-id>
                </element-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Prahallad</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</article-title>
                  <source>Nature</source>
                  <year>2012</year>
                  <volume>483</volume>
                  <fpage>100</fpage>
                  <lpage>103</lpage>
                  <pub-id pub-id-type="pmid">22281684</pub-id>
                </element-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bollag</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Hirth</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Tsai</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</article-title>
                  <source>Nature</source>
                  <year>2010</year>
                  <volume>467</volume>
                  <fpage>596</fpage>
                  <lpage>599</lpage>
                  <pub-id pub-id-type="pmid">20823850</pub-id>
                </element-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yaeger</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cercek</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>O'Reilly</surname>
                      <given-names>EM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <fpage>1313</fpage>
                  <lpage>1320</lpage>
                  <pub-id pub-id-type="pmid">25589621</pub-id>
                </element-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Van Geel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Elez</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Bendell</surname>
                      <given-names>JC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2014</year>
                  <issue>suppl</issue>
                  <fpage>32</fpage>
                  <comment>abstr 3514</comment>
                </element-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rajagopalan</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bardelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lengauer</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status</article-title>
                  <source>Nature</source>
                  <year>2002</year>
                  <volume>418</volume>
                  <fpage>934</fpage>
                  <pub-id pub-id-type="pmid">12198537</pub-id>
                </element-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tie</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gibbs</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lipton</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation</article-title>
                  <source>Int J Cancer</source>
                  <year>2011</year>
                  <volume>128</volume>
                  <fpage>2075</fpage>
                  <lpage>2084</lpage>
                  <pub-id pub-id-type="pmid">20635392</pub-id>
                </element-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fransen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Klintenas</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Osterstrom</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas</article-title>
                  <source>Carcinogenesis</source>
                  <year>2004</year>
                  <volume>25</volume>
                  <fpage>527</fpage>
                  <lpage>533</lpage>
                  <pub-id pub-id-type="pmid">14688025</pub-id>
                </element-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nazarian</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation</article-title>
                  <source>Nature</source>
                  <year>2010</year>
                  <volume>468</volume>
                  <fpage>973</fpage>
                  <lpage>977</lpage>
                  <pub-id pub-id-type="pmid">21107323</pub-id>
                </element-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahronian</surname>
                      <given-names>LG</given-names>
                    </name>
                    <name>
                      <surname>Sennott</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Van Allen</surname>
                      <given-names>EM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations</article-title>
                  <source>Cancer Discov</source>
                  <year>2015</year>
                  <volume>5</volume>
                  <fpage>358</fpage>
                  <lpage>367</lpage>
                  <pub-id pub-id-type="pmid">25673644</pub-id>
                </element-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dadu</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Busaidy</surname>
                      <given-names>NL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience</article-title>
                  <source>J Clin Endocrinol Metab</source>
                  <year>2015</year>
                  <volume>100</volume>
                  <fpage>E77</fpage>
                  <lpage>E81</lpage>
                  <pub-id pub-id-type="pmid">25353071</pub-id>
                </element-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Peters</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Michielin</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Zimmermann</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma</article-title>
                  <source>J Clin Oncol</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <fpage>e341</fpage>
                  <lpage>e344</lpage>
                  <pub-id pub-id-type="pmid">23733758</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec>
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Phase II Pilot Study of Vemurafenib in Patients With Metastatic <italic>BRAF</italic>-Mutated Colorectal Cancer</title>
                <p><italic>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="http://jco.ascopubs.org/site/ifc">jco.ascopubs.org/site/ifc</ext-link></italic>.</p>
              </sec>
              <sec>
                <title>Scott Kopetz</title>
                <p><bold>Consulting or Advisory Role:</bold> Amgen, Roche, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, Agendia, Merrimack, Sysmex, Bayer, Taiho Pharmaceutical, Sanofi, Array BioPharma</p>
                <p><bold>Research Funding:</bold> Roche, Amgen, GlaxoSmithKline, Sanofi, Sysmex, Biocartis, Guardant Health, Agendia</p>
              </sec>
              <sec>
                <title>Jayesh Desai</title>
                <p><bold>Consulting or Advisory Role:</bold> Bayer, Novartis, Merck Serono, Bionomics, Vegenics</p>
                <p><bold>Research Funding:</bold> Novartis, GlaxoSmithKline, Roche</p>
              </sec>
              <sec>
                <title>Emily Chan</title>
                <p><bold>Consulting or Advisory Role:</bold> Amgen, Lilly, Castle Biosciences, Bayer, Taiho Pharmaceutical</p>
                <p><bold>Research Funding:</bold> Millennium, Aduro Biotech, Halozyme, Amgen, Merrimack, Bristol-Myers Squibb, Karyopharm Therapeutics, Boehringer Ingelheim, Taiho Pharmaceutical, Dekkun Corporation</p>
              </sec>
              <sec>
                <title>Joel Randolph Hecht</title>
                <p><bold>Consulting or Advisory Role:</bold> Amgen, Sanofi, Genentech</p>
                <p><bold>Research Funding:</bold> GlaxoSmithKline, Novartis, OncoMed, Immunomedics, Amgen, Celgene, Pfizer, Gilead Sciences</p>
              </sec>
              <sec>
                <title>Peter J. O'Dwyer</title>
                <p><bold>Consulting or Advisory Role:</bold> Genentech, Bristol-Myers Squibb</p>
                <p><bold>Research Funding:</bold> Genentech, Genentech, GlaxoSmithKline, Novartis, Pfizer, Mirati, BBI, Bayer, Celgene, Merck, Millennium, Bristol-Myers Squibb</p>
              </sec>
              <sec>
                <title>Dipen Maru</title>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, Houston, TX - Advisory Board Member</p>
              </sec>
              <sec>
                <title>Van Morris</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec>
                <title>Filip Janku</title>
                <p><bold>Consulting or Advisory Role:</bold> Trovagene, Deciphera</p>
                <p><bold>Research Funding:</bold> Biocartis, Trovagene, BioMed Valley Discoveries, Novartis, Astellas Pharma, Plexxikon</p>
              </sec>
              <sec>
                <title>Arvind Dasari</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec>
                <title>Woonbook Chung</title>
                <p>No relationship to disclose</p>
              </sec>
              <sec>
                <title>Jean-Pierre J. Issa</title>
                <p><bold>Stock or Other Ownership:</bold> Exelixis</p>
                <p><bold>Honoraria:</bold> GlaxoSmithKline, Janssen, Teva</p>
                <p><bold>Consulting or Advisory Role:</bold> Astex Pharmaceuticals, GlaxoSmithKline</p>
                <p><bold>Research Funding:</bold> Astex Pharmaceuticals</p>
                <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Biomarkers of Cancer</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Astex Pharmaceuticals, Janssen</p>
              </sec>
              <sec>
                <title>Peter Gibbs</title>
                <p><bold>Honoraria:</bold> Roche, Amgen, Bayer, Merck, Sirtex Medical, Alchemia</p>
                <p><bold>Research Funding:</bold> Roche (Inst), Pfizer (Inst)</p>
              </sec>
              <sec>
                <title>Brian James</title>
                <p><bold>Employment:</bold> Biogen Idec (I)</p>
                <p><bold>Stock or Other Ownership:</bold> Biogen Idec (I), Amgen (I)</p>
              </sec>
              <sec>
                <title>Garth Powis</title>
                <p><bold>Stock or Other Ownership:</bold> Oncothyreon, PHusis Therapeutics</p>
                <p>
                  <bold>Patents, Royalties, Other Intellectual Property:</bold>
                </p>
              </sec>
              <sec>
                <title>Keith B. Nolop</title>
                <p><bold>Employment:</bold> Kite Pharma</p>
                <p><bold>Leadership:</bold> Kite Pharma</p>
                <p><bold>Stock or Other Ownership:</bold> Kite Pharma</p>
                <p><bold>Consulting or Advisory Role:</bold> Nuevolution</p>
              </sec>
              <sec>
                <title>Suman Bhattacharya</title>
                <p><bold>Employment:</bold> Medivation</p>
                <p><bold>Leadership:</bold> Medivation</p>
                <p><bold>Stock or Other Ownership:</bold> Medivation</p>
              </sec>
              <sec>
                <title>Leonard Saltz</title>
                <p><bold>Consulting or Advisory Role:</bold> Boehringer Ingelheim, Sun Pharma, Roche/Genentech, Pfizer, Bayer, Lilly, McNeil PPC (I), Abbvie</p>
                <p><bold>Research Funding:</bold> Taiho Pharmaceutical</p>
              </sec>
            </sec>
            <app-group>
              <app id="app1">
                <title>Appendix</title>
                <fig id="FA1" position="anchor">
                  <label>Fig A1.</label>
                  <caption>
                    <p>Development of keratoacanthoma while on therapy. (A) Before initiation of therapy and (B) after 8 weeks of treatment. (C and D) Development of multiple keratoacanthomas requiring treatment discontinuation.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560004"/>
                </fig>
                <fig id="FA2" position="anchor">
                  <label>Fig A2.</label>
                  <caption>
                    <p>Mean steady-state concentration-time profile of patients with metastatic colorectal cancer (CRC) compared with patients with melanoma treated with vemurafenib 960 mg twice per day.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560005"/>
                </fig>
                <fig id="FA3" position="anchor">
                  <label>Fig A3.</label>
                  <caption>
                    <p>Response by positron emission tomography to vemurafenib. (Top) Baseline scan. (Bottom) After one cycle of vemurafenib.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560006"/>
                </fig>
                <fig id="FA4" position="anchor">
                  <label>Fig A4.</label>
                  <caption>
                    <p>(A) Progression-free survival (PFS) for patients with or without identified alterations resulting in PI3K pathway activation (as denoted in <xref ref-type="fig" rid="F2">Fig 2</xref>). (B) PFS for patients with tumors with intact or absent EGFR expression by immunohistochemistry.</p>
                  </caption>
                  <graphic xlink:href="zlj9991056560007"/>
                </fig>
              </app>
            </app-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
